Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00090974 · ClinicalTrials.gov registry record
Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer
A clinical trial of Breast Cancer, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- 20
- Study locations
NCT00090974: Completed study of Breast Cancer, sponsored by Eastern Cooperative Oncology Group.
NCT00090974 is a study of Breast Cancer that has completed, run by Eastern Cooperative Oncology Group. The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00090974, a study of Breast Cancer, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- 20
- Study locations
Study Summary
RATIONALE: Quality-of-life assessment in postmenopausal women who are receiving hormone therapy for breast cancer may help to determine the effects of treatment on these patients and may improve the quality of life for future breast cancer patients. PURPOSE: This clinical trial is studying quality of life of postmenopausal women who are receiving either exemestane or anastrozole with or without celecoxib for stage I, stage II, or stage IIIA primary breast cancer.
Conditions Studied
Interventions
- PROCEDURE quality-of-life assessment
Study Locations (20)
California
- North Bay Cancer Center - Fairfield
- Glendale Memorial Hospital Comprehensive Cancer Center - Glendale
- Memorial Medical Center Cancer Services - Modesto
- Comprehensive Cancer Center at Desert Regional Medical Center - Palm Springs
Colorado
- Front Range Cancer Specialists - Fort Collins
- Poudre Valley Hospital - Fort Collins
- North Colorado Medical Center - Greeley
- McKee Medical Center - Loveland
Florida
- Michael & Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital - Fort Lauderdale
- Memorial Cancer Institute at Memorial Regional Hospital - Hollywood
- Ella Milbank Foshay Cancer Center at Jupiter Medical Center - Jupiter
- CCOP - Mount Sinai Medical Center - Miami Beach
Arizona
- Banner Good Samaritan Medical Center - Phoenix
- CCOP - Western Regional, Arizona - Phoenix
- Banner Thunderbird Medical Center - Phoenix
Georgia
- John B. Amos Community Cancer Center - Columbus
- Northeast Georgia Medical Center - Gainesville
Illinois
- Rush-Copley Cancer Care Center - Aurora
- Decatur Memorial Hospital Cancer Care Institute - Decatur
Alaska
- Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital - Fairbanks
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-01-26 |
| Est. Completion | 2013-01-30 |
What the finished NCT00090974 record still lists
NCT00090974 is an observational study that tracks outcomes without assigning an intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which quality-of-life assessment is the first listed.
NCT00090974 names 20 study sites across 7 states, led by California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT00090974 about?
NCT00090974 is a clinical study titled "Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer". RATIONALE: Quality-of-life assessment in postmenopausal women who are receiving hormone therapy for breast cancer may help to determine the effects of treatment on these patients and may improve the quality of life for future breast cancer patients. PURPOSE: This clinical trial is studying quality ...
What is the current status of trial NCT00090974?
This trial is currently completed. The study started on 2005-01-26. Estimated completion is 2013-01-30.
What conditions does trial NCT00090974 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00090974?
The interventions under investigation include: quality-of-life assessment (PROCEDURE).
Who is sponsoring clinical trial NCT00090974?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00090974 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI